Obstructive sleep apnea (OSA) is a prevalent condition affecting an estimated 26% of adults aged 30 to 70 in the United States, with over 25 million adults diagnosed. OSA occurs when the throat muscles relax excessively during sleep, blocking the airway and leading to interrupted breathing. This can result in sleep deprivation and increase the risk of chronic health issues such as high blood pressure, heart disease, and stroke.
Current treatment options for OSA primarily aim to keep the airway open. These include lifestyle changes, continuous positive airway pressure (CPAP) devices, mouthpieces, and, in severe cases, surgical interventions. However, many patients struggle with CPAP masks due to discomfort.
Apnimed, Inc. has recently reported promising topline results from its Phase 3 clinical trial for AD109, a potential new oral medication for OSA. The SynAIRgy trial involved 646 participants who were either unable or unwilling to use CPAP. Results indicated that 51.2% of those taking AD109 experienced a reduction in OSA severity, with nearly 22.3% achieving complete control of their condition.
AD109 combines two active ingredients aimed at enhancing nerve signals that control upper airway muscles. The trial showed a 55.6% average reduction in the apnea-hypopnea index (AHI), a key measure of OSA severity. Participants also demonstrated improved blood oxygen levels, with no serious adverse events reported.
As Apnimed prepares to submit a New Drug Application to the FDA by early 2026, AD109 could become the first prescription medication specifically targeting OSA, providing a new option for patients who find existing treatments challenging. Further results from a second Phase 3 trial are anticipated by late 2025.